Newswire (Published: Wednesday, May 15, 2019, Received: Wednesday, May 15, 2019, 7:16:05 PM CDT)
Word Count: 418
2019 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting from Houston, Texas, by NewsRx journalists, research stated, “Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured.”
Financial support for this research came from Bayer HealthCare Pharmaceuticals.
The news correspondents obtained a quote from the research from the University of Texas M.D. Anderson Cancer Center, “However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intensive therapy. This unmet need has led to recent advances in therapy aimed at treating bone metastases resulting from prostate cancer. The bone microenvironment lends itself to metastases in castrate-resistant prostate cancer, as a result of complex interactions between the microenvironment and tumor cells. The development of (223)-radium dichloride (Ra-223) to treat symptomatic bone metastases has improved survival in men with metastatic castrate-resistant prostate cancer. Moreover, Ra-223 may have effects on the tumor microenvironment that enhance its activity. Ra-223 treatment has been shown to prolong survival, and its effects on the immune system are under investigation. Because prostate cancer affects a sizable portion of the adult male population, understanding how it metastasizes to bone is an important step in advancing therapy.”
According to the news reporters, the research concluded: “Clinical trials that are underway should yield new information on whether Ra-223 synergizes effectively with immunotherapy agents and whether Ra-223 has enhancing effects on the immune system in patients with prostate cancer.”
For more information on this research see: Current Perspectives On Bone Metastases In Castrate-resistant Prostate Cancer. Cancer and Metastasis Reviews, 2018;37(1):189-196. Cancer and Metastasis Reviews can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Cancer and Metastasis Reviews - http://www.springerlink.com/content/0167-7659/)
Our news journalists report that additional information may be obtained by contacting C. Logothetis, M.D. Anderson Cancer Center, Houston, TX 77030, United States. Additional authors for this research include M.J. Morris, R. Den and R.E. Coleman.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10555-017-9719-4. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Bayer Healthcare Pharmaceuticals Inc.
The University of Texas MD Anderson Cancer Center
MD Anderson Cancer Center
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Treatments and Therapies